Ribociclib Shown to Penetrate the Blood-Brain Barrier in Glioblastoma
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors.
Head and Neck Cancer
Immunological Profiling of High-Grade Gliomas Reveals Subtypes That Influence Survival
Four distinct immunologic groups independent of patient age were identified and correlated with overall survival in patients with high-grade glioma.
Baseline Dysphagia May Predict Response to Treatment, Survival in Esophageal Cancer
Patients with higher dysphagia scores also experienced worse febrile neutropenia and diarrhea.
Comparison Study Shows Predictive Value for CSCC of the Head and Neck of BWH vs AJCC 8
A team of researchers sought to determine if BWH Tumor Classification System classified tumors more accurately than AJCC 8, and their sensitivity and specificity for predicting poor outcomes.
Does Radioactive Iodine Treatment for Hyperthyroidism Confer A Higher Cancer Risk?
Over the past decade, researchers have found inconsistent evidence about whether radioactive iodine treatment for hyperthyroidism can cause cancer in the long term.
Following NCCN Surveillance Guidelines in Oropharyngeal Carcinoma Did Not Yield a Survival Benefit: Study
Patients with HPV–associated oropharyngeal squamous cell carcinoma who adhered to the NCCN clinical surveillance recommendations did have improved survival.
Tapping Into the Therapeutic Expertise of High-Volume Cancer Centers
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems.
Minority, Low-Income Individuals Less Likely to Receive Oral Cancer Screening
Education level, insurance type also may affect likelihood of oral cancer screening at dental visit.
Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech).
Treatment Reduction in Intermediate-Risk Neuroblastoma Deemed Successful
For specific subsets of patients with intermediate-risk neuroblastoma, an algorithm successfully reduced treatment while maintaining survival outcomes.
